| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Elastase from porcine pancreas targets peptide bonds adjacent to neutral amino acid residues in proteins and peptides. As a serine protease, it catalyzes the hydrolysis of these bonds. The enzyme is used as a positive control in protease assays and for studying elastase inhibition.
|
|---|---|
| ln Vitro |
Protocol for digestion 1. Resuspend elastase until it reaches a final concentration of 1 mg/mL in double-distilled water. For two weeks, resuspension elastase can be kept at 4°C. 2. In reaction buffer (50 mM Tris-HCl, pH 8.5–9.5, or another reaction buffer containing TRIS, pH 4.0–10.0), resuspend the protein; 3. Use an enzyme to protein solution ratio of 1:20 to 1:100; 4. Add elastase to the protein solution. 5. Incubate for 2–18 hours at 37°C. To stop the reaction, add 10% formic acid or TFA to a final concentration of 0.5% or heat it for 10 minutes at 95°C.
In vitro, Elastase from porcine pancreas hydrolyzes proteins and peptides, particularly at bonds adjacent to neutral amino acids. One unit of enzyme activity is defined as the amount required to hydrolyze 1 mg of Congo red-elastin within 30 minutes at 37°C, pH 7.0. The enzyme's molecular weight is 25,898.13. |
| ln Vivo |
In hamsters, elastase from the porcine pancreas causes emphysema[3].
In vivo, Elastase from porcine pancreas is not used as a therapeutic agent but as a research tool. It has been used to treat Vero cells to study its effects on syncytium formation and to identify a novel bone/calcium metabolism-regulating factor in porcine pancreas. The enzyme has no direct therapeutic applications. |
| Enzyme Assay |
Cell-free assays for Elastase from porcine pancreas involve measuring the enzyme's activity using chromogenic or fluorogenic substrates such as N-succinyl-Ala-Ala-Ala-p-nitroanilide (AAAPVN) or Congo red-elastin. Enzyme activity is monitored spectrophotometrically by measuring the release of p-nitroaniline or the hydrolysis of elastin. Activity is expressed in units per mg of protein.
|
| Cell Assay |
In vitro cellular assays are not typically performed with Elastase from porcine pancreas as a direct cell treatment, although it has been used to treat Vero cells to study syncytium formation. The enzyme is more commonly used in cell-free systems or in tissue homogenates to digest proteins or to study protease inhibition.
|
| Animal Protocol |
In vivo animal studies are not applicable for Elastase from porcine pancreas as a therapeutic agent. The enzyme is used ex vivo for protein digestion and research applications. Its role in pancreatic physiology is studied in the context of digestion, but it is not administered to animals as a drug.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not relevant for Elastase from porcine pancreas as it is an enzyme used in laboratory research rather than a therapeutic agent. The enzyme is not administered systemically; it is used in vitro for biochemical applications such as protein digestion and protease assays.
|
| Toxicity/Toxicokinetics |
Toxicological data are not applicable for Elastase from porcine pancreas as it is a research enzyme, not a therapeutic compound. Standard laboratory safety practices apply when handling the enzyme. No systemic toxicity studies have been conducted, as it is not intended for human use.
|
| References |
|
| Additional Infomation |
Elastase from porcine pancreas is a research enzyme with no clinical applications. It is widely used in biochemistry for protein digestion, protease assays, and as a positive control in inhibition studies. The enzyme's specificity for neutral amino acid residues makes it a valuable tool for studying protein structure and function. It is also used in studies investigating elastase inhibitors for therapeutic applications.
|
| Molecular Formula |
C20H31N4O7CL
|
|---|---|
| Molecular Weight |
474.93574
|
| CAS # |
39445-21-1
|
| Appearance |
White to off-white solid powder
|
| SMILES |
COC(CCC(N[C@@H](C(N[C@@H](C(N1CCC[C@@H]1C(N[C@@H](C(CCl)=O)C)=O)=O)C)=O)C)=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (1.93 mM)
H2O: 1 mg/mL (0.04 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1055 mL | 10.5276 mL | 21.0553 mL | |
| 5 mM | 0.4211 mL | 2.1055 mL | 4.2111 mL | |
| 10 mM | 0.2106 mL | 1.0528 mL | 2.1055 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA